Locatelli et al. Am J Nephrol 2017;45: (DOI: / )

Slides:

Advertisements

Similar presentations

Matt Macoul BMCB 658 4/6/2012. Effects of High Altitudes  Low oxygen pressure Hypoxia  Not just from altitude Heart Attack Stroke  Affects cellular.

Advertisements

© 2016 S. Karger AG, Basel. All rights reserved Metabolomics of Chronic Kidney Disease Progression: A Case-Control Analysis in the Chronic Renal Insufficiency.

Updates From Kidney Week Chronic Kidney Disease and Associated Anemia

A.M. Thompson, T.G. Pickering Kidney International

A Proton Pump Inhibitor a Day Keeps the Iron Away

The MASS-DAC Study.

Importance of Ferritin for Optimizing Anemia Therapy in Chronic Kidney Disease Am J Nephrol 2010;32:439–446 - DOI: / Fig. 1. Estimated.

Renal Parenchymal Hypoxia, Hypoxia Response and the Progression of Chronic Kidney Disease Am J Nephrol 2008;28:998– DOI: / © 2008.

Pulmonary Hypertension Is Associated with Mortality and Cardiovascular Events in Chronic Kidney Disease Patients Am J Nephrol 2017;45: DOI: /

Effect of Food Insecurity on Chronic Kidney Disease in Lower-Income Americans Am J Nephrol 2014;39: DOI: / Fig. 1. Age-adjusted.

Algorithm for iron therapy in management of anemia of CKD

Volume 88, Issue 5, Pages (November 2015)

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD Nupur Gupta, MD, Jay B. Wish, MD American.

Iain C. Macdougall, BSc, MD, FRCP American Journal of Kidney Diseases

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Advancing Management of Anemia With the Latest Data From ERA-EDTA 2018

Acute Kidney Injury and In-Hospital Mortality after Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention: A Nationwide Study Shen et.

New and Emerging Management Options for Anemia in CKD

Kuwabara et al. Am J Nephrol 2017;45: (DOI: / )

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:

Bhandari et al. Am J Nephrol 2017;45: (DOI: / )

New options for the anemia of chronic kidney disease

Use of Erythropoiesis-Stimulating Agents in Patients With Anemia of Chronic Kidney Disease: Overcoming the Pharmacological and Pharmacoeconomic Limitations.

American Journal of Kidney Diseases

Change in mean LVMI with erythropoietin alpha hemoglobin maintenance treatment and control/delayed treatment from baseline to 24 months End point Hemoglobin.

Mitchell H. Rosner, W. Kline Bolton Kidney International

Bushinsky et al. Am J Nephrol 2016;44: (DOI: / )

Impact of Cognitive Function Change on Mortality in Renal Transplant and End-Stage Renal Disease Patients Sharma et al. Am J Nephrol 2016;44: (DOI: / )

Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology.

The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease

Figure 1 The burden of chronic kidney disease (CKD)

Obstacles and Advances in Anemia Management in Patients With CKD

Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease Torres et al. Am J.

Hammoud et al. Am J Nephrol 2016;44: (DOI: / )

PK-M2 Makes Cells Sweeter on HIF1

ESA and iron therapy in chronic kidney disease: a balance between patient safety and hemoglobin target Szu-Chun Hung, Der-Cherng Tarng Kidney International

Figure 5 Potential roles of phosphate and fibroblast growth factor 23 (FGF-23) in the development of cardiovascular disease in patients with chronic kidney.

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD Nupur Gupta, MD, Jay B. Wish, MD American.

Managing CKD-Associated Anemia in Challenging Patients

Yasuhiro Hamada, Masafumi Fukagawa Kidney International

Pregnancy Outcomes in Patients with Glomerular Disease Attending a Single Academic Center in North Carolina O'Shaughnessy et al. Am J Nephrol 2017;45:

Volume 62, Issue 2, Pages (August 2002)

History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology Kalantar-Zadeh Am J Nephrol.

Volume 70, Pages S21-S25 (December 2006)

The Hypoxic Response: Huffing and HIFing

A Proton Pump Inhibitor a Day Keeps the Iron Away

Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects Akizawa et.

Nat. Rev. Nephrol. doi: /nrneph

Langsford et al. Am J Nephrol 2017;45: (DOI: / )

Payan Schober et al. Am J Nephrol 2017;45: (DOI: / )

Kidney Disease Among African Americans: A Population Perspective

Volume 78, Issue 7, Pages (October 2010)

Volume 78, Issue 8, Pages (October 2010)

Insight from the Air–Skin Interface

Francesco Locatelli, Lucia Del Vecchio Kidney International

Nowak et al. Am J Nephrol 2016;44: (DOI: / )

Targeting Immunity in End-Stage Renal Disease

Volume 80, Issue 5, Pages (September 2011)

Incidence of contrast-induced nephropathy in patients with CKD, normal kidney function and all patients. Incidence of contrast-induced nephropathy in patients.

Hypoxia and fibrosis in chronic kidney disease: crossing at pericytes

Volume 76, Issue 5, Pages (September 2009)

Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis.

Niels Grote Beverborg et al. JCHF 2018;6:

Regulation of Intestinal Iron Absorption: The Mucosa Takes Control?

PK-M2 Makes Cells Sweeter on HIF1

Schematic diagram of the HIF-signalling system and zebrafish homologues. Schematic diagram of the HIF-signalling system and zebrafish homologues. (A) Proteins.

Anemia Explored.

Challenges and Emerging Solutions in Anemia Management Explored

Schematic representation of the mechanisms underlying anemia of CKD

Fistula and Survival Outcomes after Fistula Creation among Predialysis Chronic Kidney Disease Stage 5 Patients Miyamoto et al. Am J Nephrol 2017;45:

Presentation transcript:

Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients Locatelli et al. Am J Nephrol 2017;45:187-199 (DOI:10.1159/000455166) Fig. 1. The role of hepcidin, iron, and erythropoietin in erythropoiesis. CKD, chronic kidney disease; EPO, erythropoietin.

Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients Locatelli et al. Am J Nephrol 2017;45:187-199 (DOI:10.1159/000455166) Fig. 2. a, b HIF activity under normoxic/hypoxic conditions and HIF-PHI inhibition, and its effects on erythropoiesis. DCytB, duodenal cytochrome B; DMT1, Divalent metal transporter 1; EPO, erythropoietin; HIF, hypoxia-inducible factor; HIF-PH, hypoxia-inducible factor-prolyl-4-hydroxylase domain; HRE, HIF-responsive element; Pro, proline.

Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients Locatelli et al. Am J Nephrol 2017;45:187-199 (DOI:10.1159/000455166) Table 1. HIF-PHIs in clinical development